ENTITY

Oryzon Genomics (ORY SM)

53
Analysis
Health CareSpain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Refresh
bullishOryzon Genomics
06 Dec 2023 01:10Issuer-paid

Oryzon Genomics - Grant to bolster ALS pipeline, add funding

Oryzon has announced the receipt of a $0.5m grant from the Amyotrophic Lateral Sclerosis (ALS) Association to support the regulatory clinical...

Share
bullishOryzon Genomics
28 Nov 2023 07:10Issuer-paid

Oryzon Genomics - Key €45m funding to back strategic priorities

Oryzon has secured funding of up to €45m through a revised convertible bond financing agreement with Nice & Green, a Switzerland-based...

Share
bullishOryzon Genomics
07 Nov 2023 01:10Issuer-paid

Oryzon Genomics - Q323 recap ahead of key clinical stages

Oryzon’s Q323 results recapped the clinical progression across its drug development pipeline. The company continues to develop therapies that...

Share
bullishOryzon Genomics
12 Oct 2023 01:10Issuer-paid

Oryzon Genomics - Favorable safety reported in PORTICO Phase II

Oryzon presented a positive update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the ECNP Congress....

Share
bullishOryzon Genomics
05 Oct 2023 01:10Issuer-paid

Oryzon Genomics - Grants provide confidence and expand portfolio

Oryzon has announced that it has received two separate grants from the Spanish State Research Agency and the Ministry of Science and Innovation to...

Share
x